Some Perspective & The Big Picture
There are a few on this thread that do just seem to lack some perspective and/or expect a ridiculously early outcome;
Pacific Edge have very clearly and consistently told us that they anticipate a market share of 10% in the US to be achieved after 5 years time. That represents 1 urologist in 10 coming on board and using Cxbladder in 5 years time from now, yes that's five years from now.
Urine based bladder cancer tests have been used by clinicians within the US for over 10 years and insurers have been paying those bill’s for over 10 years. For Cxbladder to enter the market with superior tech, it initially becomes a matter of taking a little market share off the incumbent competition and then, because Cxbladder is superior to cytology, expanding and achieving that 10% market penetration 5 years later.
In New Zealand we have a differently structured health system, urine based diagnostic tests are not entrenched as they are in the US, if even used at all, and Pacific Edge must start from scratch.
The NZ health system is not as commercially accountable to insurers as in the US, and there is less focus on optimising long run patient care value outcomes. Pacific Edge are doing the correct thing in working with the HIH in this respect and over time that should change.
As investors, we should not expect every urologist to adopt Cxbladder, Pacific Edge don’t, they expect 10% of them to do so, and they have allowed a full 5 years for that in the US, possibly longer for New Zealand.
Try some patience folks, you will feel better, go away enjoy your life, come back in five years,